Index

Abrams JS, 551
African American Study of Kidney Disease and Hypertension, 555
Agodoa LY, 555
Aickin M, 145, 551
AIDS Clinical Trials Group, 554, 555
Alzheimer's Disease Anti-inflammatory Prevention Trial, 551, 553
Amplatz K, 551
analysis
analysis dataset, 415
Bayesian analysis, 419
exploratory data analysis, 265, 423
final data analysis, 421
frequentist, 383, 419
frequentist analysis, 419
interim data analysis, 373
likelihoodist, 419
masked data analysis, 107
subgroup analysis, 265, 423
assignment
adaptive treatment assignment, 145, 263
baseline adaptive treatment assignment, 145
biased coin treatment assignment, 145
fixed treatment assignment, 145
masked treatment assignment, 108, 147
minimum likelihood treatment assignment, 145
number adaptive treatment assignment, 145
open treatment assignment, 147
outcome adaptive treatment assignment, 146
play-the-winner treatment assignment, 146
treatment assignment ratio, 146, 151
treatment assignment stratum, 152
treatment assignment visit, 272
urn model treatment assignment, 146
author/authorship
author, 431
author citation, 431
authorship, 431
authorship attribution, 431
conventional author, 431
conventional author citation, 431
conventional authorship, 431
corporate author, 431
corporate author citation, 432
corporate authorship, 432
modified conventional author citation, 432
modified conventional authorship, 432
modified corporate author citation, 432
modified corporate authorship, 432
Vancouver Convention, 432
baseline
baseline, 271
baseline adaptive treatment assignment, 145
baseline examination, 271
baseline period, 271, 275
minimum likelihood treatment assignment, 145
Baum RA, 554
Bayes T, 419, 551
Bayes’ theorem, 419
Begg C, 551
bias
biased coin treatment assignment, 145
conflict of interest, 463
counter, 132
definition, 131
selection, 149
treatment-related bias, 132
treatment-related feedback bias, 132
treatment-related selection bias, 132
Bissett JK, 551
block/blocking
block, 151
block size, 151
blocked randomization, 151
permuted block, 151
board
central institutional review board, 163
commercial institutional review board, 163
independent institutional review board, 164
local institutional review board, 164
parent institutional review board, 164
Boissel J-P, 551
Brain Resuscitation Clinical Trial II Study Group, 172, 189, 551
Breitner JCS, 553
Brittain E, 88, 97, 203, 551
Buchwald H, 231, 232, 551
Campbell GS, 551
Campos CT, 551
Canner PL, 551, 554
Canto MI, 552
Cardiac Arrhythmia Suppression Trial, 551
Cardiac Arrhythmia Suppression Trial Investigators, 97, 203
Castaneda-Zuniga WR, 551
censor/censored
informative censoring, 113
uninformative censoring, 114
center
center director, 331
center representation construct, 367
central laboratory (CL), 287
definition, 317, 325
lead center, 164
parent center, 164, 317
reading center (RC), 289
resource center, 318
satellite center, 318
study center, 318
study center director, 332
Chalmers TC, 551
Chang M, 551
Chemoprevention for Barrett’s Esophagus Trial, 552
Childhood Asthma Management Program, 554
Childhood Asthma Management Program Research Group, 551
Cho M, 551
Chow S-C, 551
Christian MC, 551
clinic
clinic coordinator, 333
definition, 317
lead clinic, 203
study clinic coordinator, 333
study clinic monitor, 405
closeout
anniversary closing date, 225
close of followup, 217
closeout design, 225
closeout examination, 271
closeout followup visit, 225, 271
closeout period, 275
closeout stage, 225
common closing date, 225
post-closeout followup visit, 272
Collet J-P, 551
committee
executive committee (EC), 353
key committee, 339
masked treatment effects monitoring committee, 108
performance monitoring committee, 399
standing committee, 341
steering committee (SC), 359
working committee, 341
comparison
comparison group, 73
comparison treatment, 73, 79
designed subgroup comparison, 265
subgroup comparison, 266, 423
compliance
followup compliance, 217
treatment compliance, 98
treatment compliance measure, 98
consent
active consent, 189
consent form, 172
consent process, 185
consent statement, 172
consent, documentation of, 169
consent, elements of, 170
consent, requirement of, 172
deconsent, 172
deferred consent, 172, 189
documented consent, 189
implied consent, 189
informed consent, 173
oral consent, 173
passive consent, 189
reconsent, 173
signed consent, 173
witnessed consent, 189
Consolidated Standards of Reporting Trials (CONSORT), 232
control
active control treatment, 79
alternative control treatment, 79
best medical judgment control treatment, 79
control treatment, 79
control-assigned group, 71
control-treated group, 71
inactive control treatment, 79
negative control treatment, 80
nil treatment control, 80
placebo control, 87
placebo-control treatment, 89
positive control treatment, 80
sham procedure, 91
trace control treatment, 80
controlled
placebo-controlled trial, 89
coordinating center
resource center, 318
Cornfield J, 419, 551
Coronary Drug Project, 56, 88, 97, 203, 551, 552
credit roster, 436
Criner GJ, 552  
crossover  
crossover treatment, 103  
treatment crossover, 103  
Dannenberg AJ, 552  
data  
analysis dataset, 415  
bolus data flow, 283  
centralized data entry, 301  
continuous data flow, 283  
data collection site, 317  
data coordinator, 333  
data dictionary, 307, 311  
data dredging, 265, 423  
data editing, 285  
data element, 285  
data entry, 301  
data field, 285  
data flow, 283  
data form, 285  
data freeze, 285, 415  
data generation, 285  
data generation site, 285, 317  
data keying, 285  
data management, 286  
data purge, 286  
data query, 286  
data record, 286  
data sharing, 311  
data snapshot, 286  
data system, 286  
data transcription, 286  
data transformation, 286  
data use agreement, 311  
dataset, 415  
deidentified data, 307  
dependent double data entry, 301  
direct data entry, 301  
distributed data entry, 301  
double data entry, 301  
electronic data form, 301  
exploratory data analysis, 265, 423  
external data sharing, 307, 312  
final data analysis, 421  
final dataset, 421  
followup data, 217  
frozen data, 415  
frozen dataset, 415  
identified data, 307, 312  
independent double data entry, 302  
indirect data entry, 302  
interim data analysis, 373  
internal data sharing, 307, 312  
keyless data recording, 302  
limited use dataset, 312  
linkable data, 307  
mandated data sharing, 312  
masked data analysis, 107  
masked data collection, 107  
on-line data entry, 302  
paper data form, 302  
paperless data entry, 302  
PC-based data entry, 302  
public use dataset, 312  
quasi-independent double data entry, 302  
real-time data entry, 283  
web-based data entry, 302  
data analysis  
exploratory data analysis, 265, 423  
final data analysis, 421  
interim data analysis, 373  
data collection  
data collection site, 317  
editing and processing, 305  
masked, 111  
masked data collection, 107  
data editing  
rules, 398  
data entry  
considerations, 305  
Davis KB, 552  
DeAngelis CD, 552, 553  
Definitions  
acknowledgment, 435  
active consent, 189  
active control treatment, 79  
active followup, 217, 221  
adaptive study design, 263  
adaptive treatment assignment, 145, 263  
administrative review, 399  
adverse drug experience, 471  
adverse drug reaction, 471  
adverse event, 471  
adverse reaction, 471  
adverse side effect, 472  
adverse treatment effect, 472  
advocacy representation construct, 367  
alpha spending function, 383  
alternative control treatment, 79  
alternative treatment, 79  
analysis dataset, 415  
ancillary publication, 417, 427  
ancillary study, 459  
anniversary closing date, 225  
appointed study chair, 349  
aristocracy representation construct, 367  
assent, 169  
assent form, 169
Definitions (cont.)

assent statement, 169
audit, 409
audit trail, 409
author, 431
author citation, 431
authorship, 431
authorship attribution, 431
award statement, 51
baseline, 271
baseline adaptive treatment assignment, 145
baseline examination, 271
baseline period, 271, 275
baseline results paper, 417
batch number, 117
Bayes’ theorem, 419
Bayesian, 383, 419
Bayesian analysis, 419
best and final offer, 51
best medical judgment control treatment, 79
bias, 131
biased coin treatment assignment, 145
bin number drug system, 117
blacklist, 403
blackout, 127
blind, 107
blister pack, 117
block, 151
block size, 151
blocked randomization, 151
bolus data flow, 283
business office, 51
case report form, 283
censor, 113
center, 317, 325
center director, 331
center representation construct, 367
central IRB, 163
central laboratory, 287
centralized data entry, 301
centralized funding, 51
Certificate of Confidentiality, 181
certification, 403
circuit rider, 405
clinic, 317
clinic coordinator, 333
clinic start-up design, 203
clinical equipoise, 75
clinical research associate, 333
clinical trial, xvii
close of followup, 217
closed sequential design, 253
closeout design, 225
closeout examination, 271
closeout followup visit, 225, 271
closeout period, 275
closeout stage, 225
cluster randomization, 155
do-, 331
do-investigator, 331
commercial IRB, 163
common closing date, 225
comparison group, 73
comparison treatment, 73, 79
competitive bid, 51
competitive bidding, 51
competitive funding, 51
competitive initiative, 51
competitive proposal, 51
competitive range, 51
competitive renewal, 52
complete randomized, 151
concealed treatment assignment, 147
concealment, 107
concurrent followup, 217
conflict of interest, 463
consent, 169
consent form, 172
consent process, 185
consent statement, 172
consent, documentation of, 169
consent, elements of, 170
consent, requirement of, 172
consortium funding, 52
consortium funding agreement, 52
consortium funding award, 52
continuous data flow, 283
contract office, 52
contract officer, 52
contract proposal, 52
control treatment, 79
control-assigned group, 71
control-treated group, 71
conventional author, 431
conventional author citation, 431
conventional authorship, 431
cooperative agreement, 52
core funding, 52
corporate author, 431
corporate author citation, 432
corporate authorship, 432
credit, 435
crossover treatment, 103
data collection site, 317
data coordinator, 333
data dictionary, 307, 311
data dredging, 265, 423
data editing, 285
data element, 285
data entry, 301
<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>data field, 285</td>
<td></td>
</tr>
<tr>
<td>data file, 285</td>
<td></td>
</tr>
<tr>
<td>data flow, 283</td>
<td></td>
</tr>
<tr>
<td>data form, 285</td>
<td></td>
</tr>
<tr>
<td>data freeze, 285, 415</td>
<td></td>
</tr>
<tr>
<td>data generation, 285</td>
<td></td>
</tr>
<tr>
<td>data generation site, 285, 317</td>
<td></td>
</tr>
<tr>
<td>data harvest, 415</td>
<td></td>
</tr>
<tr>
<td>data keying, 285</td>
<td></td>
</tr>
<tr>
<td>data management, 286</td>
<td></td>
</tr>
<tr>
<td>data purge, 286</td>
<td></td>
</tr>
<tr>
<td>data query, 286</td>
<td></td>
</tr>
<tr>
<td>data record, 286</td>
<td></td>
</tr>
<tr>
<td>data sharing, 311</td>
<td></td>
</tr>
<tr>
<td>data snapshot, 286</td>
<td></td>
</tr>
<tr>
<td>data system, 286</td>
<td></td>
</tr>
<tr>
<td>data transcription, 286</td>
<td></td>
</tr>
<tr>
<td>data transformation, 286</td>
<td></td>
</tr>
<tr>
<td>data use agreement, 311</td>
<td></td>
</tr>
<tr>
<td>dataset, 415</td>
<td></td>
</tr>
<tr>
<td>debarment, 403</td>
<td></td>
</tr>
<tr>
<td>deconsent, 172</td>
<td></td>
</tr>
<tr>
<td>deferred consent, 172, 189</td>
<td></td>
</tr>
<tr>
<td>deidentified data, 307, 311</td>
<td></td>
</tr>
<tr>
<td>deidentify, 307</td>
<td></td>
</tr>
<tr>
<td>dependent double data entry, 301</td>
<td></td>
</tr>
<tr>
<td>deputy director, 331</td>
<td></td>
</tr>
<tr>
<td>design variable, 35</td>
<td></td>
</tr>
<tr>
<td>designed subgroup comparison, 265</td>
<td></td>
</tr>
<tr>
<td>detectable difference, 257</td>
<td></td>
</tr>
<tr>
<td>direct data entry, 301</td>
<td></td>
</tr>
<tr>
<td>direct distribution of funds, 52</td>
<td></td>
</tr>
<tr>
<td>direct followup, 221</td>
<td></td>
</tr>
<tr>
<td>direct funding award, 53</td>
<td></td>
</tr>
<tr>
<td>direct followup, 221</td>
<td></td>
</tr>
<tr>
<td>direct funding award, 53</td>
<td></td>
</tr>
<tr>
<td>discipline representation construct, 367</td>
<td></td>
</tr>
<tr>
<td>disclosure form, 463</td>
<td></td>
</tr>
<tr>
<td>distributed data entry, 301</td>
<td></td>
</tr>
<tr>
<td>distributed funding, 53</td>
<td></td>
</tr>
<tr>
<td>distribution of funds, 53</td>
<td></td>
</tr>
<tr>
<td>documented consent, 189</td>
<td></td>
</tr>
<tr>
<td>double data entry, 301</td>
<td></td>
</tr>
<tr>
<td>double mask, 107</td>
<td></td>
</tr>
<tr>
<td>double placebo, 115</td>
<td></td>
</tr>
<tr>
<td>dropout, 231</td>
<td></td>
</tr>
<tr>
<td>dropout compensation, 232</td>
<td></td>
</tr>
<tr>
<td>dropout replacement, 232</td>
<td></td>
</tr>
<tr>
<td>drug reaction, 472</td>
<td></td>
</tr>
<tr>
<td>efficacy monitoring, 375</td>
<td></td>
</tr>
<tr>
<td>elected study chair, 349</td>
<td></td>
</tr>
<tr>
<td>electronic data form, 301</td>
<td></td>
</tr>
<tr>
<td>endpoint, 39</td>
<td></td>
</tr>
<tr>
<td>ex officio, 347</td>
<td></td>
</tr>
<tr>
<td>executive committee, 353</td>
<td></td>
</tr>
<tr>
<td>expedited review, 161</td>
<td></td>
</tr>
<tr>
<td>experimental variable, 31</td>
<td></td>
</tr>
<tr>
<td>exploratory data analysis, 265, 423</td>
<td></td>
</tr>
<tr>
<td>external data sharing, 307, 312</td>
<td></td>
</tr>
<tr>
<td>extramural funding, 53</td>
<td></td>
</tr>
<tr>
<td>feasibility study, 203</td>
<td></td>
</tr>
<tr>
<td>fee-for-service, 67</td>
<td></td>
</tr>
<tr>
<td>flat study chair, 349</td>
<td></td>
</tr>
<tr>
<td>final, 421</td>
<td></td>
</tr>
<tr>
<td>final data analysis, 421</td>
<td></td>
</tr>
<tr>
<td>final dataset, 421</td>
<td></td>
</tr>
<tr>
<td>final treatment result, 421</td>
<td></td>
</tr>
<tr>
<td>finder’s fee, 455</td>
<td></td>
</tr>
<tr>
<td>frozen sample size design, 254, 261</td>
<td></td>
</tr>
<tr>
<td>fixed study design, 263</td>
<td></td>
</tr>
<tr>
<td>fixed treatment assignment, 145</td>
<td></td>
</tr>
<tr>
<td>fixed-cost, 67</td>
<td></td>
</tr>
<tr>
<td>followup, 217, 272</td>
<td></td>
</tr>
<tr>
<td>followup cohort, 217</td>
<td></td>
</tr>
<tr>
<td>followup compliance, 217</td>
<td></td>
</tr>
<tr>
<td>followup data, 217</td>
<td></td>
</tr>
<tr>
<td>followup observation, 217</td>
<td></td>
</tr>
<tr>
<td>followup period, 217, 223, 275</td>
<td></td>
</tr>
<tr>
<td>followup stage, 217</td>
<td></td>
</tr>
<tr>
<td>followup study, 217</td>
<td></td>
</tr>
<tr>
<td>followup study design, 218</td>
<td></td>
</tr>
<tr>
<td>followup visit, 218, 272</td>
<td></td>
</tr>
<tr>
<td>form, 295</td>
<td></td>
</tr>
<tr>
<td>frequentist, 383, 419</td>
<td></td>
</tr>
<tr>
<td>frequentist analysis, 419</td>
<td></td>
</tr>
<tr>
<td>frozen data, 415</td>
<td></td>
</tr>
<tr>
<td>frozen dataset, 415</td>
<td></td>
</tr>
<tr>
<td>frozen state of equipoise, 131</td>
<td></td>
</tr>
<tr>
<td>funding agency, 53</td>
<td></td>
</tr>
<tr>
<td>funding agreement, 53</td>
<td></td>
</tr>
<tr>
<td>funding application, 53</td>
<td></td>
</tr>
<tr>
<td>funding award, 53</td>
<td></td>
</tr>
<tr>
<td>funding office, 53</td>
<td></td>
</tr>
<tr>
<td>funding officer, 53</td>
<td></td>
</tr>
<tr>
<td>funding period, 53, 63</td>
<td></td>
</tr>
<tr>
<td>funding proposal, 53</td>
<td></td>
</tr>
<tr>
<td>funding request, 53</td>
<td></td>
</tr>
<tr>
<td>Gantt chart, 241</td>
<td></td>
</tr>
<tr>
<td>grant, 53</td>
<td></td>
</tr>
<tr>
<td>grant application, 54</td>
<td></td>
</tr>
<tr>
<td>grants management office, 54</td>
<td></td>
</tr>
<tr>
<td>grants management officer, 54</td>
<td></td>
</tr>
<tr>
<td>group randomization, 155</td>
<td></td>
</tr>
<tr>
<td>group sequential design, 254</td>
<td></td>
</tr>
<tr>
<td>haphazard, 147</td>
<td></td>
</tr>
<tr>
<td>haphazardization, 147</td>
<td></td>
</tr>
<tr>
<td>harm, 373</td>
<td></td>
</tr>
<tr>
<td>head fee, 67</td>
<td></td>
</tr>
<tr>
<td>home visit, 272</td>
<td></td>
</tr>
<tr>
<td>ideal time window, 299</td>
<td></td>
</tr>
<tr>
<td>identified data, 307, 312</td>
<td></td>
</tr>
<tr>
<td>implied consent, 189</td>
<td></td>
</tr>
<tr>
<td>implied consent, 189</td>
<td></td>
</tr>
</tbody>
</table>
Definitions (cont.)

inactive control treatment, 79
incentive, 455
incentive payment, 455
incremental funding, 54, 67
independent double data entry, 302
independent institutional review board, 164
indirect data entry, 302
indirect distribution of funds, 55
indirect followup, 221
indirect funding award, 55
individual randomization, 155
informative censoring, 113
informed consent, 173
insider, 463
insider information, 464
insider trading, 464
institutional review board, 161, 164
interim data analysis, 373
interim followup, 218
interim followup visit, 272
interim look, 373
interim result, 373
internal data sharing, 307, 312
intramural funding, 55
investigational new drug safety report, 472
investigator, 331
investigator-initiated research proposal, 55
involve, 161
jack-up factor, 257
key committee, 339
keyless data acquisition, 302
laboratory, 287
lead center, 164
lead clinic, 203
lead-in period, 97, 203
likelihood principle, 419
likelihoodist, 383, 419
limited use dataset, 312
linkable data, 307
local IRB, 164
local laboratory, 287
loss to followup, 218, 235
losses to followup, 218
lost to followup, 218, 235
lot number, 117
main study, 467
mainline paper, 417, 427
mandated data sharing, 312
mask, 107, 114
masked data analysis, 107
masked data collection, 107
masked randomization, 107
masked reading, 108
masked treater, 108
masked treatment, 108
masked treatment administration, 108
masked treatment assignment, 108
masked treatment effects monitoring, 108, 379
masked treatment effects monitoring committee, 108
masked treatment effects monitoring report, 379
masked trial, 108
masking level, 108
med Id number drug system, 117
minimal risk, 161
minimization, 145
minimum likelihood treatment assignment, 145
missed study visit, 229
mock treatment, 91
modified conventional author citation, 432
modified conventional authorship, 432
modified corporate author citation, 432
modified corporate authorship, 432
monitor, 409
more than minimal risk, 162
multi-study, 19
multi-study structure, 353
multicenter study, xvii
multiple placebo, 115
natural history study, 427
negative control treatment, 80
nil treatment, 80
nil treatment control, 80
noncompetitive proposal, 55
noncompetitive renewal, 55
nonrequired followup study, 218
nonrequired followup visit, 272
null treatment, 80
number adaptive treatment assignment, 145
officers of the study, 347
on-line data entry, 302
open sequential design, 254
open treatment assignment, 147
oral consent, 173
outcome, 40
outcome adaptive treatment assignment, 146
outcome event, 40
outcome measure, 40
outcome variable, 40
overrepresent, 213
paired treatment design, 33
paper data form, 302
paperless data entry, 302
parent center, 164, 317
parent IRB, 164
parent study, 467
passive consent, 189
passive followup, 218, 221
patient contact schedule, 269
patient mail contact, 269
patient telephone contact, 269
PC-based data entry, 302
performance monitoring, 399
performance monitoring committee, 399
performance monitoring report, 399
performance review, 399
permissible time window, 299
permuted block, 151
PI representation construct, 367
pill count, 97
pilot study, 204
placebo, 87
placebo control, 87
placebo effect, 80, 88
placebo group, 88
placebo lead-in period, 88
placebo patient, 88
placebo period, 88
placebo reactor, 88
placebo treatment, 88
placebo treatment effect, 88
placebo washout, 88
placebo-assigned, 89
placebo-assigned group, 89
placebo-assigned patient, 89
placebo-control treatment, 89
placebo-controlled trial, 89
placebo-treated, 89
placebo-treated group, 89
placebo-treated patient, 89
play-the-winner treatment assignment, 146
positive control treatment, 80
post-closeout followup visit, 272
post-treatment followup, 218
post-trial followup, 219
post-trial followup stage, 219
power, 257
presentation, 427, 439
primacy, right of, 308
primary outcome, 35
primary outcome measure, 35
primary outcome variable, 35
primary publication, 417, 427
primary result, 427
principal investigator, 331
prospective followup, 219
protocol bailout, 103
protocol deviation, 101
protocol override, 101
protocol violation, 101
pseudorandom, 147
public repository, 293
public use dataset, 312
publication, 427
quality assurance, 395
quality control, 395
quasi-independent double data entry, 302
quasirandom, 147
quota, 213
quota requirement, 213
quotification, 213
random, 147
randomization, 148
randomization unit, 155
randomized controlled trial, xvii
reading center, 289
real-time data entry, 283
recompete, 55
recompetition, 55
reconsent, 173
record audit, 409
recruitment quota, 213
reference group, 73
registration, 495
regular followup visit, 219, 272
renewal, 55
reportable event, 472, 475
reported event, 476
repository, 293
representation construct, 368
representativeness, 214
request for application, 56
request for proposal, 56
required followup visit, 219, 272
research, 162
research contract proposal, 56
research grant, 56
research grant application, 56
research grant proposal, 56
research group, 335
resource center, 318
restricted randomization, 151
results blackout, 127, 308
results paper, 417
retrospective followup, 219
rotating study chair, 349
run-in period, 97, 204
safety monitoring, 375
safety report, 473
satellite center, 318
scheduled followup, 219
scheduled study visit, 272
secondary paper, 417
secondary publication, 427
sequential design, 254
sequential sample size design, 255, 261
DeMets DL, 552
Department of Health and Human Services, 552
design
  adaptive study design, 263
  clinic start-up design, 203
  closed sequential design, 253
  closeout design, 225
  design variable, 35
  designed subgroup comparison, 265
  fixed sample size design, 254, 261
  fixed study design, 263
  followup study design, 218
  group sequential design, 254
  open sequential design, 254
  paired treatment design, 33
  sequential design, 254
  sequential sample size design, 255, 261
deviation/deviate
  protocol deviation, 101
Diabetic Retinopathy Study, 53, 552
Dickson WJ, 554
Diggle P, 552
Drazen JM, 552, 553
drug
  adverse drug experience, 471
  adverse drug reaction (ADR), 471
  bin number drug system, 117
  blister pack, 117
  drug reaction, 472
  investigational new drug safety report, 472
  med Id number drug system, 117
  serious adverse drug experience, 473
  unexpected adverse drug experience, 474
Dunnett CW, 552
Dupont WD, 419, 552
Eastwood S, 551
Edmiston WA, 551
Edwards AWF, 552
effect
  masked treatment effects monitoring, 108
  placebo effect, 80
  sham effect, 91
  treatment effects monitoring, 373
error
  type I error, 257
  type II error, 257
event
  adverse event, 471
FDA related terms
  adverse drug experience, 471
  adverse drug reaction (ADR), 471
  adverse side effect, 472
  blacklist, 403
drug reaction, 472
  investigational new drug safety report, 472
  safety report, 473
  serious adverse drug experience, 473
  sponsor, 56
  unexpected adverse drug experience, 474
Fisher L, 552
Fitch LL, 551
followup
  active followup, 217, 221
  close of followup, 217
  closeout followup visit, 225, 271
  concurrent followup, 217
  direct followup, 221
  followup, 217, 272
  followup cohort, 217
  followup compliance, 217
  followup data, 217
  followup observation, 217
  followup period, 217, 223, 275
  followup stage, 217
  followup study, 217
  followup study design, 218
  followup visit, 218, 272
  indirect followup, 221
  interim followup, 218
  interim followup visit, 272
  loss to followup, 218, 235
  losses to followup, 218
  lost to followup, 218, 235
  nonconcurrent followup study, 218
  nonrequired followup visit, 272
  passive followup, 218, 221
  post-closeout followup visit, 272
  post-treatment followup, 218
  post-trial followup, 219
  post-trial followup stage, 219
  prospective followup, 219
  regular followup visit, 219, 272
  required followup visit, 219, 272
  retrospective followup, 219
  scheduled followup, 219
  treatment application and adjustment
    followup visit, 272
  unscheduled followup, 219
  unscheduled followup visit, 272
Food and Drug Administration (FDA), 409, 552
Forastiere AA, 552
Forman S, 554
Fost N, 172, 189, 552
Freedman B, 75, 552
Friedman B, 146, 552
Friedman MA, 551
Frizelle FA, 552, 553
funding
  award statement, 51
  best and final offer, 51
  centralized funding, 51
  competitive bid, 51
  competitive bidding, 51
  competitive funding, 51
  competitive initiative, 51
  competitive proposal, 51
  competitive range, 51
  competitive renewal, 52
  consortium funding, 52
  consortium funding agreement, 52
  consortium funding award, 52
  contract office, 52
  contract officer, 52
  contract proposal, 52
  cooperative agreement, 52
  core funding, 52
  direct distribution of funds, 52
  direct funding award, 53
  distributed funding, 53
  distribution of funds, 53
  extramural funding, 53
  funding agency, 53
  funding agreement, 53
  funding application, 53
  funding award, 53
  funding office, 53
  funding officer, 53
  funding period, 53, 63
  funding proposal, 53
  funding request, 53
  grant, 53
  grant application, 54
  grant vs contract, 61
  incremental funding, 54, 67
  indirect distribution of funds, 55
  indirect funding award, 55
  intramural funding, 55
  investigator initiated, 61
  investigator-initiated research proposal, 55
  methods of initiation, 61
  noncompetitive proposal, 55
  noncompetitive renewal, 55
  recompete, 55
  recompetition, 55
  renewal, 55
  request for application, 56
  request for proposal, 56
  research contract proposal, 56
  research grant, 56
  research grant application, 56
  research grant proposal, 56
  sponsor-initiated research proposal, 56
  subcontract, 57
  subcontractor, 57

Gillespie MJ, 552
Glassock R, 555
Glaucoma Laser Trial, 33, 53, 552
Glaucoma Laser Trial Research Group, 33
Godlee F, 553

group
  control-assigned group, 71
  group randomization, 155
  subgroup, 265, 423
  subgroup analysis, 265, 423
  subgroup comparison, 266, 423
  subgroup treatment difference, 423
  subgrouping cutpoint, 266, 424
  subgrouping variable, 424
  test-assigned group, 71

Habig RL, 554
Hansen BJ, 551
Hanson RF, 554
Harlan WR, 555
Haug C, 552, 553
Haugh M, 551
Hawk E, 552
Health Insurance Portability and Accountability Act (HIPAA)
de-identified data, 307
Heath EI, 552
Hébert PC, 553
Herman JG, 552
Hersh T, 554
Hightower NC Jr, 554
Hippocratic Oath, 373
Hoey J, 552
Hoffmann AF, 554
Horton R, 551–553
Hunter DW, 551
Hypertension Detection and Follow-up Program, 552
Hypertension Prevention Trial, 553

Ide NC, 555
identification
de-identify, 307
linkable data, 307
Ingelfinger FJ, 553
Institute of Medicine, 553
institution
  commercial institutional review board, 163
  institutional review board (IRB), 161, 164
  assent, 169
  assent form, 169
  assent statement, 169
central institutional review board, 163
consent, 169
consent form, 172
consent process, 185
consent, requirement of, 172
documented consent, 189
expedited review, 161
finder’s fee, 455
incentive, 455
incentive payment, 455
independent institutional review board, 164
informed consent, 173
involve, 161
local institutional review board, 164
parent institutional review board, 164
renewal, 55
research, 162
International Committee of medical Journal
Editors, 553
Kaplan RS, 551
Karnegis JN, 551
Katz J, 553
Kenward MG, 552
Kirk KA, 555
Klimt CR, 553
Knatterud GL, 553
Korn EL, 551
Kotzin S, 552, 553
Kusek JW, 555
Lachin JM, 146, 553–555
Laine C, 552, 553
Lakatos E, 555
Lan KKG, 552
Lasser EC, 554
Lee JY, 555
Leon AS, 551
Levine RJ, 172, 189, 553
likelihood
likelihood principle, 419
Lindberg DAB, 555
Lind JM, 551
Macular Photocoagulation Study Group, 553
Marks JW, 553, 554
Martin BK, 553
Marusic A, 552, 553
mask/masking
blinded, 107
double mask, double masked, 107
mask, 107
mask, masked, 107
mask, masked, masking, masks, 107, 114
masked data analysis, 107
masked data collection, 107
masked randomization, 107
masked reading, 108
masked reader, 108
masked treatment, 108
masked treatment administration, 108
masked treatment assignment, 108, 147
masked treatment effects monitoring, 108,
379
masked treatment effects monitoring
committee, 108
masked treatment effects monitoring report,
379
masked trial, 108
masking level, 108
principles, 111
shields, 114, 127
single masked, single mask, 108
treatment administration, 111
triple-mask, triple-masked, 109
unmask, unmasked, 109
unmask, unmasked, unmasking, unmasks, 109
Usage note, 107
Matts JP, 551
McCabe MS, 551
McCuskey RF, 554
Meier P, 553
Meinert CL, 553
Mekhjian H, 554
model
urn model, 146
urn model randomization, 146
Moher D, 551
Moleur P, 551
monitor/monitoring
administrative review, 399
efficacy monitoring, 375
interim look, 373
masked treatment effects monitoring, 108,
379
masked treatment effects monitoring
committee, 108
masked treatment effects monitoring report,
379
monitor, monitored, monitoring, monitors,
409
performance monitoring, 399
performance monitoring committee, 399
performance monitoring report, 399
performance review, 399
safety monitoring, 375
study clinic monitor, 405
treatment effects monitoring, 373
Montgomery E, 552
Multiple Risk Factor Intervention Trial, 553
National Cooperative Gallstone Study, 553, 554
National Emphysema Treatment Trial, 554
National Emphysema Treatment Trial Research Group, 553
National Heart, Lung, and Blood Institute, 554
National Institutes of Health (NIH), 554, 555

number
batch number, 117
Norton V, 554

Office for Protection from Research Risks (OPRR), 554
office/officer
business office, 51
contract office, 52
contract officer, 52
funding office, 53
funding officer, 53
grants management office, 54
grants management officer, 54
officers of the study, 347

office/officer
study officers, 347

Okun R, 554
Olkin I, 551

organization
desired separations, 141

outcome
outcome, 40
outcome adaptive treatment assignment, 146
outcome event, 40
outcome measure, 40
outcome variable, 40
primary outcome, 35
primary outcome measure, 35
primary outcome variable, 35

Overbeke AJPM, 552

patient/person
trial-proper patient, 204

Pearce MB, 551

period
baseline period, 271, 275
Persantine-Aspirin Reinfarction Study, 554
Pettinger M, 552
Physicians' Health Study, 554
Piantadosi S, 552
Pitkin R, 551

placebo
double placebo, 115
multiple placebo, 115
placebo, 87
placebo control, 87
placebo effect, 80, 88
placebo group, 88
placebo lead-in period, 88
placebo patient, 88
placebo period, 88
placebo reactor, 88
placebo treatment, 88
placebo treatment effect, 88
placebo washout, 88
placebo-assigned, 89
placebo-assigned group, 89
placebo-assigned patient, 89
placebo-control treatment, 89
placebo-controlled trial, 89
placebo-treated, 89
placebo-treated group, 89
placebo-treated patient, 89
single placebo, 115

Pocock SJ, 145, 554
post-stratification vs stratification, 137

power
arcsin approximation, 260
definition, 257
normal approximation, 260
Poisson approximation, 260
Prentice RL, 554
probability
Bayes' theorem, 419
likelihood principle, 419
Probstfield J, 555
Program on the Surgical Control of the Hyperlipidemias, 232, 551

proposal
competitive proposal, 51
protocol
protocol bailout, 103
protocol deviation, 101
protocol override, 101
protocol violation, 101
treatment protocol suspension, 103

publication
ancillary publication, 417, 427
baseline results paper, 417
primary publication, 417, 427
publication, 427
results paper, 417
secondary publication, 427

quality control
aids, 397
credos, 397
pitfalls, 398
planning aids, 397
requirements, 397
Randall OS, 555
random/randomized
  pseudorandom, 147
  quasi-random, 147
  random, 147
randomization
  blocked randomization, 151
  cluster randomization, 155
  complete randomization, 151
  features, 149
  group randomization, 155
  haphazardization, 147
  individual randomization, 155
  masked randomization, 107
  misconceptions, 149
  randomization, 148
  randomization unit, 155
  restricted randomization, 151
  urn model randomization, 146
record
  record audit, 409
recruitment
  recruitment quota, 213
Rennie D, 551
research
  clinical research associate, 333
result
  final treatment result, 421
  interim result, 373
  primary result, 427
  results blackout, 127, 308
review
  central institutional review board, 163
  commercial institutional review board, 163
  independent institutional review board, 164
  local institutional review board, 164
  parent institutional review board, 164
right
  primacy, right of, 308
Robbins H, 146, 554
Robertson JA, 172, 189, 552
Robin ED, 554
Roethlisberger FJ, 554

Sahmi P, 553
sample size
  fixed sample size design, 254, 261
  jack-up factor, 257
  sequential sample size design, 255, 261
Sanmarco ME, 551
Sawin HS, 551
Schafer RA, 554
Schlant RC, 554
Shoenfield LJ, 553, 554
Schroeder TV, 552, 553
Schultz KF, 551
Shar AO, 552
Shaw L, 554
Shimm DS, 554
side effect
  adverse drug experience, 471
  adverse side effect, 472
  safety report, 473
  serious adverse drug experience, 473
  unexpected adverse drug experience, 474
Simel D, 551
Simon R, 145, 263, 554
Smink Jr RD, 551
Soloway RD, 554
Sox HC, 552, 553
Spece RG, 554
Stamler J, 553, 554
start-up
  clinic start-up design, 203
  start-up patients, 204
  test patients, 204
  vanguard patients, 204
Stevenson JW, 551
stratification
  considerations, 136
  variable, 136
  when to, 136
stratify/stratification
  stratify, 135
Stroup DF, 551
Studies of Ocular Complications of AIDS, 554, 555
study
  adaptive study design, 263
  ancillary study, 459
  feasibility study, 203
  fixed study design, 263
  followup study, 217
  followup study design, 218
  main study, 467
  missed study visit, 229
  multi-study structure, 353
  natural history study, 427
  nonconcurrent followup study, 218
  officers of the study, 347
  parent study, 467
  pilot study, 204
  study center director, 332
  study chair, 349
  study chair external, 349
  study chair internal, 349
  study result, 417
  study vice-chair, 349
  substudy, 467
study index
  Coronary Drug Project, 117
  Glaucoma Laser Trial, 33
  Program on the Surgical Control of the Hyperlipidemias, 551
subgroup
  designed subgroup comparison, 265
  subgrouping, 266
  subgrouping variable, 266
Systolic Hypertension in the Elderly Program, 53, 554
Taves DR, 145, 555
test
  test-assigned group, 71
  test-treated group, 71
theorem
  Bayes’ theorem, 419
Thistle JL, 554
Thomas FB, 554
Tonascia S, 553
Toto RD, 555
treatment
  active control treatment, 79
  alternative control treatment, 79
  alternative treatment, 79
  best medical judgment control treatment, 79
  comparison treatment, 73, 79
  control treatment, 79
  crossover treatment, 103
  final treatment result, 421
  inactive control treatment, 79
  masked treatment, 108
  masked treatment administration, 108
  mock treatment, 91
  negative control treatment, 80
  nil treatment, 80
  nil treatment control, 80
  null treatment, 80
  placebo treatment, 88
  placebo-control treatment, 89
  positive control treatment, 80
  post-treatment followup, 218
  sham treatment, 91
  standard treatment, 73, 80
  study treatment, 75
  subgroup treatment difference, 423
  test treatment, 77
  test-treated group, 71
  trace control treatment, 80
  trace treatment, 80
  treatment application and adjustment
    followup visit, 272
  treatment cessation, 103
  treatment change, 103
  treatment compliance, 98
  treatment compliance measure, 98
  treatment group, 71
  treatment lag, 257
  treatment modality, 93
  treatment period, 276
  treatment protocol suspension, 103
  treatment schedule, 95
  treatment suspension, 104
  treatment switch, 104
  treatment termination, 104
  treatment unit, 33
  treatment variable, 31
  treatment-related bias, 132
  treatment-related feedback bias, 132
  treatment-related selection bias, 132
  treatment assignment
    adaptive treatment assignment, 145, 263
    baseline adaptive treatment assignment, 145
    biased coin treatment assignment, 145
    bin number drug system, 117
    cluster randomization, 155
    fixed treatment assignment, 145
    group randomization, 155
    individual randomization, 155
    masked treatment assignment, 108, 147
    med Id number drug system, 117
    minimum likelihood treatment assignment, 145
    number adaptive treatment assignment, 145
    open treatment assignment, 147
    outcome adaptive treatment assignment, 146
    play-the-winner treatment assignment, 146
    randomization, see also, 148
    treatment assignment ratio, 146, 151
    treatment assignment stratum, 152
    treatment assignment visit, 272
    urn model treatment assignment, 146
  treatment crossover
    treatment crossover, 103
  treatment design
    paired treatment design, 33
treatment effect
  masked treatment effects monitoring, 108, 379
  masked treatment effects monitoring committee, 108
  masked treatment effects monitoring report, 379
  placebo treatment effect, 88
  treatment effects monitoring, 373
trial
  masked trial, 108
  placebo-controlled trial, 89
  post-trial followup, 219
post-trial followup stage, 219
trial-proper, 204
trial-proper patient, 204
Tse T, 555
Tuna N, 551
Tyor MP, 554
Tyroler HA, 555

United States Congress, 555
University Group Diabetes Program, 80, 87, 131, 491, 555
University Group Diabetes Program Research Group, 555

usage note
adaptive study design, 263
administrative review, 399
adverse drug reaction (ADR), 471
adverse event, 471
adverse reaction, 471
ancillary study, 459
assent, 169
audit, 409
audit, audited, auditing, audits, 409
author, 431
authorship, 431
authorship attribution, 431
baseline, 271
baseline examination, 271
baseline period, 271, 275
bias, 131
blind, 107
block, 151
censor, censored, censoring, censors, 113
center, 317, 325
clinical equipoise, 75
c, 331
commercial institutional review board, 163
comparison treatment, 73, 79
competitive bidding, 51
competitive range, 51
competitive renewal, 52
concealment, 107
conflict of interest, 463
consent, 169
contract office, 52
contract officer, 52
cost treatment, 79
cost-assigned group, 71
cost-treated group, 71
data collection site, 317
data dredging, 265, 423
data generation site, 285, 317
dataset, 415
deferred consent, 172, 189
design variable, 35
dropout, 231
dropout compensation, 232
dropout replacement, 232
drug reaction, 472
efficacy monitoring, 375
endpoint, 39
ex-officio, 347
executive committee (EC), 353
exploratory data analysis, 265, 423
final, 421
finder’s fee, 455
fixed study design, 263
followup study, 217
frequentist analysis, 419
frozen state of equipoise, 131
funding period, 53, 63
grant, 53
grants management office, 54
grants management officer, 54
haphazard, 147
haphazardization, 147
harm, 373
identified data, 307, 312
implied consent, 189
incentive, 455
incentive payment, 455
informed consent, 173
insider, 463
insider trading, 464
investigator, 331
investigator-initiated research proposal, 55
involve, involved, involving, involves, 161
lead-in period, 97, 203
linkable data, 307
loss to followup, 218, 235
lost to followup, 218, 235
mask, 107
masked randomization, 107
masked treatment assignment, 108
masking level, 108
monitor, monitored, monitoring, monitors, 409
multi-study structure, 353
noncompetitive renewal, 55
outcome, 40
passive consent, 189
PC-based data entry, 302
performance monitoring, 399
performance review, 399
placebo, 87
placebo control, 87
placebo effect, 80, 88
placebo group, 88
placebo patient, 88
usage note (cont.)
placebo treatment, 88
placebo treatment effect, 88
placebo-assigned, 89
placebo-assigned group, 89
placebo-assigned patient, 89
placebo-control treatment, 89
placebo-controlled trial, 89
placebo-treated, 89
placebo-treated group, 89
placebo-treated patient, 89
post-treatment followup, 218
presentation, 427, 439
primary outcome, 35
principal investigator (PI), 331
protocol bailout, 103
protocol deviation, 101
pseudorandom, 147
public repository, 293
publication, 427
quality assurance, 395
quality control, 395
quasirandom, 147
quota requirement, 213
quotification, 213
random, 147
randomization, 148
record audit, 409
recruitment quota, 213
registration, 495
regular followup visit, 219, 272
reportable event, 472, 475
reported event, 476
repository, 293
request for application (RFA), 56
request for proposal (RFP), 56
research grant, 56
retrospective followup, 219
run-in period, 97, 204
safety monitoring, 375
sequential sample size design, 255, 261
sham, 91
sham procedure, 91
sponsor-initiated research proposal, 56
standard treatment, 73, 80
start-up patients, 204
steering committee (SC), 359
stopping guideline, 381
stopping rule, 381
stratification, 135
stratify, 135
study center, 318
study group, 71

subcontract, 57
subcontractor, 57
subgroup analysis, 265, 423
substudy, 467
test patients, 204
test treatment, 77
test-treated group, 71
treatment crossover, 103
treatment effects monitoring, 373
treatment protocol suspension, 103
treatment-related feedback bias, 132
triple-mask, triple-masked, 109
underrepresent, underrepresented,
underrepresents, 214
understudy, understudied, understudying,
understudies, 214
vanguard patients, 204
withdrawal, 232

Van Der Weyden MB, 552, 553
Varco RL, 551
variable
design variable, 35
experimental variable, 31
outcome variable, 40
primary outcome variable, 35
stratification variable, 135
subgrouping variable, 266, 424
treatment variable, 31
variance
control, 139, 140
reduction, 140
reduction via analysis, 140
variance, 139
Verheugt FWA, 553
visit
closeout followup visit, 225, 271
followup visit, 218, 272
home visit, 272
interim followup visit, 272
missed study visit, 229
nonrequired followup visit, 272
post-closeout followup visit, 272
regular followup visit, 219, 272
required followup visit, 219, 272
scheduled study visit, 272
site visit, 405
study visit, 272
treatment application and adjustment
followup visit, 272
treatment assignment visit, 272
unscheduled followup visit, 272
Weber FJ, 551
Wei LJ, 146, 555
Weinstein WM, 552
West JC, 555
Winau R, 555
Wittes J, 88, 97, 203, 551, 555
Wright JT Jr, 555
Yang VW, 552
Yellin AE, 551
Yusuf S, 555
Zarin DA, 555
Zelen M, 146, 555